Naïve T-Cell Depletion to Prevent GVHD: Searching for a Better Mousetrap

Soiffer, Robert J.

doi:10.1200/jco.22.00105

JCO

2022

DOI: 10.1200/jco.22.00105

|View full text |Cite

Naïve T-Cell Depletion to Prevent GVHD: Searching for a Better Mousetrap

Robert J. Soiffer

Abstract: The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I 5 Immediate Family Member, Inst 5 My Institution. Relationships may not relate to the subject matter of this manuscript.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy

Maurer,

Antin

2024

Front. Immunol.

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy for many hematologic malignancies as well as non-malignant conditions. Part of the curative basis underlying HSCT for hematologic malignancies relies upon induction of the graft versus leukemia (GVL) effect in which donor immune cells recognize and eliminate residual malignant cells within the recipient, thereby maintaining remission. GVL is a clinically evident phenomenon; however, specific cell types responsible for inducing this effect and molecular mechanisms involved remain largely undefined. One of the best examples of GVL is observed after donor lymphocyte infusions (DLI), an established therapy for relapsed disease or incipient/anticipated relapse. DLI involves infusion of peripheral blood lymphocytes from the original HSCT donor into the recipient. Sustained remission can be observed in 20-80% of patients treated with DLI depending upon the underlying disease and the intrinsic burden of targeted cells. In this review, we will discuss current knowledge about mechanisms of GVL after DLI, experimental strategies for augmenting GVL by manipulation of DLI (e.g. neoantigen vaccination, specific cell type selection/depletion) and research outlook for improving DLI and cellular immunotherapies for hematologic malignancies through better molecular definition of the GVL effect.

show abstract

The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy

Maurer,

Antin

2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Naïve T-Cell Depletion to Prevent GVHD: Searching for a Better Mousetrap

Cited by 1 publication

References 20 publications

The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy

The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy

Contact Info

Product

Resources

About